** Shares of telehealth firm Hims and Hers HIMS.N, which offers compounded versions of weight-loss drugs, fall 20.4% to $52.8
** The U.S FDA says that a shortage of Novo Nordisk's NOVOb.CO weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved as per the agency's website
** The resolution could restrict how telehealth programs offer cheaper versions known as compounded drugs
** For HIMS and other compounders "this development starts the clock on having unfettered market access" to Novo's drugs, says brokerage Leerink Partners
** It will be critical to understand HIMS' legal pathway to selling personalized doses for semaglutide - since it is the primary way it can continue selling the drug, Leerink added
** US government regulations allow compounded versions of a branded drug to be sold to meet demand if the drug is in shortage
** Stock has risen nearly seven-fold in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。